Hikma Pharmaceuticals PLC EBITDA for the year ending December 31, 2024: USD 787.00 M

Hikma Pharmaceuticals PLC EBITDA is USD 787.00 M for the year ending December 31, 2024, a -0.51% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Hikma Pharmaceuticals PLC EBITDA for the year ending December 31, 2023 was USD 791.00 M, a 63.09% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA for the year ending December 31, 2022 was USD 485.00 M, a -34.81% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA for the year ending December 31, 2021 was USD 744.00 M, a 13.76% change year over year.
  • Hikma Pharmaceuticals PLC EBITDA for the year ending December 31, 2020 was USD 654.00 M, a 11.99% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)